_version_ 1784746154873847808
author Fresa, Alberto
Autore, Francesco
Piciocchi, Alfonso
Catania, Gioacchino
Visentin, Andrea
Tomasso, Annamaria
Moretti, Marina
Vitale, Candida
Chiarenza, Annalisa
Morelli, Francesca
Sportoletti, Paolo
Marasca, Roberto
Sapienza, Giuseppe
Cuccaro, Annarosa
Murru, Roberta
Sanna, Alessandro
Patti, Caterina
Angeletti, Ilaria
Coscia, Marta
Trentin, Livio
Pietrasanta, Daniela
Innocenti, Idanna
Laurenti, Luca
author_facet Fresa, Alberto
Autore, Francesco
Piciocchi, Alfonso
Catania, Gioacchino
Visentin, Andrea
Tomasso, Annamaria
Moretti, Marina
Vitale, Candida
Chiarenza, Annalisa
Morelli, Francesca
Sportoletti, Paolo
Marasca, Roberto
Sapienza, Giuseppe
Cuccaro, Annarosa
Murru, Roberta
Sanna, Alessandro
Patti, Caterina
Angeletti, Ilaria
Coscia, Marta
Trentin, Livio
Pietrasanta, Daniela
Innocenti, Idanna
Laurenti, Luca
author_sort Fresa, Alberto
collection PubMed
description
format Online
Article
Text
id pubmed-9278285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-92782852022-08-01 Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study Fresa, Alberto Autore, Francesco Piciocchi, Alfonso Catania, Gioacchino Visentin, Andrea Tomasso, Annamaria Moretti, Marina Vitale, Candida Chiarenza, Annalisa Morelli, Francesca Sportoletti, Paolo Marasca, Roberto Sapienza, Giuseppe Cuccaro, Annarosa Murru, Roberta Sanna, Alessandro Patti, Caterina Angeletti, Ilaria Coscia, Marta Trentin, Livio Pietrasanta, Daniela Innocenti, Idanna Laurenti, Luca Blood Adv Research Letter American Society of Hematology 2022-07-05 /pmc/articles/PMC9278285/ /pubmed/35789375 http://dx.doi.org/10.1182/bloodadvances.2022006964 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Research Letter
Fresa, Alberto
Autore, Francesco
Piciocchi, Alfonso
Catania, Gioacchino
Visentin, Andrea
Tomasso, Annamaria
Moretti, Marina
Vitale, Candida
Chiarenza, Annalisa
Morelli, Francesca
Sportoletti, Paolo
Marasca, Roberto
Sapienza, Giuseppe
Cuccaro, Annarosa
Murru, Roberta
Sanna, Alessandro
Patti, Caterina
Angeletti, Ilaria
Coscia, Marta
Trentin, Livio
Pietrasanta, Daniela
Innocenti, Idanna
Laurenti, Luca
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
title Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
title_full Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
title_fullStr Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
title_full_unstemmed Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
title_short Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
title_sort relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter italian study
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278285/
https://www.ncbi.nlm.nih.gov/pubmed/35789375
http://dx.doi.org/10.1182/bloodadvances.2022006964
work_keys_str_mv AT fresaalberto relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT autorefrancesco relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT piciocchialfonso relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT cataniagioacchino relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT visentinandrea relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT tomassoannamaria relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT morettimarina relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT vitalecandida relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT chiarenzaannalisa relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT morellifrancesca relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT sportolettipaolo relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT marascaroberto relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT sapienzagiuseppe relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT cuccaroannarosa relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT murruroberta relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT sannaalessandro relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT patticaterina relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT angelettiilaria relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT cosciamarta relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT trentinlivio relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT pietrasantadaniela relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT innocentiidanna relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy
AT laurentiluca relativedoseintensityofobinutuzumabchlorambucilinchroniclymphocyticleukemiaamulticenteritalianstudy